|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EIF5 |
Gene summary for EIF5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EIF5 | Gene ID | 1983 |
| Gene name | eukaryotic translation initiation factor 5 | |
| Gene Alias | EIF-5 | |
| Cytomap | 14q32.32 | |
| Gene Type | protein-coding | GO ID | GO:0001731 | UniProtAcc | A0A024R6Q1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1983 | EIF5 | GSM4909277 | Human | Breast | Precancer | 1.37e-05 | 5.06e-01 | 0.0177 |
| 1983 | EIF5 | GSM4909285 | Human | Breast | IDC | 3.38e-03 | -2.66e-01 | 0.21 |
| 1983 | EIF5 | GSM4909286 | Human | Breast | IDC | 1.62e-05 | -2.41e-01 | 0.1081 |
| 1983 | EIF5 | GSM4909287 | Human | Breast | IDC | 1.16e-03 | -4.08e-01 | 0.2057 |
| 1983 | EIF5 | GSM4909293 | Human | Breast | IDC | 1.17e-03 | -3.32e-01 | 0.1581 |
| 1983 | EIF5 | GSM4909294 | Human | Breast | IDC | 1.79e-04 | -3.68e-01 | 0.2022 |
| 1983 | EIF5 | GSM4909296 | Human | Breast | IDC | 7.00e-10 | -3.77e-01 | 0.1524 |
| 1983 | EIF5 | GSM4909297 | Human | Breast | IDC | 1.79e-15 | -3.42e-01 | 0.1517 |
| 1983 | EIF5 | GSM4909301 | Human | Breast | IDC | 1.59e-03 | -3.70e-01 | 0.1577 |
| 1983 | EIF5 | GSM4909302 | Human | Breast | IDC | 4.19e-11 | -5.55e-01 | 0.1545 |
| 1983 | EIF5 | GSM4909311 | Human | Breast | IDC | 6.26e-37 | -6.88e-01 | 0.1534 |
| 1983 | EIF5 | GSM4909312 | Human | Breast | IDC | 5.68e-15 | -4.79e-01 | 0.1552 |
| 1983 | EIF5 | GSM4909313 | Human | Breast | IDC | 1.26e-06 | -4.69e-01 | 0.0391 |
| 1983 | EIF5 | GSM4909319 | Human | Breast | IDC | 6.07e-43 | -6.40e-01 | 0.1563 |
| 1983 | EIF5 | GSM4909320 | Human | Breast | IDC | 3.52e-04 | -3.47e-01 | 0.1575 |
| 1983 | EIF5 | GSM4909321 | Human | Breast | IDC | 2.92e-11 | -2.65e-01 | 0.1559 |
| 1983 | EIF5 | brca1 | Human | Breast | Precancer | 1.15e-14 | 4.19e-01 | -0.0338 |
| 1983 | EIF5 | brca10 | Human | Breast | Precancer | 6.85e-05 | -4.55e-01 | -0.0029 |
| 1983 | EIF5 | NCCBC14 | Human | Breast | DCIS | 2.66e-07 | -1.32e-01 | 0.2021 |
| 1983 | EIF5 | NCCBC5 | Human | Breast | DCIS | 1.01e-11 | -3.84e-01 | 0.2046 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000173131 | Thyroid | ATC | formation of translation preinitiation complex | 9/6293 | 11/18723 | 1.46e-03 | 7.47e-03 | 9 |
| GO:003320917 | Thyroid | ATC | tumor necrosis factor-mediated signaling pathway | 48/6293 | 99/18723 | 1.51e-03 | 7.70e-03 | 48 |
| GO:004324412 | Thyroid | ATC | regulation of protein-containing complex disassembly | 56/6293 | 121/18723 | 2.51e-03 | 1.16e-02 | 56 |
| GO:004354715 | Thyroid | ATC | positive regulation of GTPase activity | 106/6293 | 255/18723 | 4.58e-03 | 1.89e-02 | 106 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| EIF5 | SNV | Missense_Mutation | c.39C>G | p.Phe13Leu | p.F13L | P55010 | protein_coding | deleterious(0.03) | possibly_damaging(0.558) | TCGA-A2-A0YL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| EIF5 | SNV | Missense_Mutation | c.238C>T | p.His80Tyr | p.H80Y | P55010 | protein_coding | deleterious(0) | benign(0.277) | TCGA-A2-A0YL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| EIF5 | SNV | Missense_Mutation | rs779336285 | c.124G>A | p.Val42Ile | p.V42I | P55010 | protein_coding | tolerated(0.55) | benign(0.013) | TCGA-D8-A1JD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| EIF5 | SNV | Missense_Mutation | c.33N>G | p.Asp11Glu | p.D11E | P55010 | protein_coding | deleterious(0) | possibly_damaging(0.87) | TCGA-E2-A14O-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | SD | |
| EIF5 | insertion | In_Frame_Ins | novel | c.321_322insTGTCTTGCAGCTTATTCGCCTCAT | p.Thr107_Asp108insCysLeuAlaAlaTyrSerProHis | p.T107_D108insCLAAYSPH | P55010 | protein_coding | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| EIF5 | insertion | Nonsense_Mutation | novel | c.507_508insCGAGGTCAGGAGTTCTAGACCAGCCTAGCCAACAT | p.Asn170ArgfsTer6 | p.N170Rfs*6 | P55010 | protein_coding | TCGA-A8-A09W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| EIF5 | insertion | Nonsense_Mutation | novel | c.311_312insCGTCTGATTGCCAAGGTAATAAACTGCTCTTCAATTTAGT | p.Pro105ValfsTer2 | p.P105Vfs*2 | P55010 | protein_coding | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| EIF5 | SNV | Missense_Mutation | novel | c.1204N>A | p.Glu402Lys | p.E402K | P55010 | protein_coding | deleterious(0.02) | benign(0.173) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| EIF5 | SNV | Missense_Mutation | novel | c.89N>G | p.Asn30Ser | p.N30S | P55010 | protein_coding | deleterious(0) | probably_damaging(0.946) | TCGA-MA-AA3Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| EIF5 | SNV | Missense_Mutation | novel | c.173N>T | p.Gly58Val | p.G58V | P55010 | protein_coding | deleterious(0) | benign(0.267) | TCGA-VS-A9V5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |